Loading…

Prospective clinical study of R-CMD therapy for indolent B cell lymphoma and mantle cell lymphoma from the Hokuriku Hematology Oncology Study Group

Standardized treatments for indolent B cell lymphoma primarily consisting of follicular lymphoma (FL) and for mantle cell lymphoma (MCL) have yet to be established. Here the Hokuriku Hematology Oncology Study Group conducted a multicenter prospective study to investigate the efficacy and safety of a...

Full description

Saved in:
Bibliographic Details
Published in:Medical oncology (Northwood, London, England) London, England), 2015-09, Vol.32 (9), p.232-232, Article 232
Main Authors: Sakai, Tomoyuki, Masaki, Yasufumi, Otsuki, Nozomi, Sakamaki, Ippei, Kishi, Shinji, Miyazono, Takayoshi, Urasaki, Yoshimasa, Murakami, Jun, Satoh, Tomomi, Nakamura, Takuji, Iwao, Haruka, Nakajima, Akio, Kawanami, Takafumi, Miki, Miyuki, Fujita, Yoshimasa, Tanaka, Masao, Fukushima, Toshihiro, Okazaki, Toshiro, Ueda, Takanori
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Standardized treatments for indolent B cell lymphoma primarily consisting of follicular lymphoma (FL) and for mantle cell lymphoma (MCL) have yet to be established. Here the Hokuriku Hematology Oncology Study Group conducted a multicenter prospective study to investigate the efficacy and safety of a combination regimen of rituximab, cladribine, mitoxantrone, and dexamethasone (R-CMD) in indolent B cell lymphoma and MCL. A total of 33 CD20-positive patients who received care between January 2008 and August 2011 were investigated. These patients’ illnesses were FL ( n  = 21), nodal marginal zone B cell lymphoma (NMZB, n  = 3), MCL ( n  = 3), splenic marginal zone B cell lymphoma ( n  = 2), hairy cell leukemia ( n  = 1), Waldenstrom macroglobulinemia (WM, n  = 1), and lymphoplasmacytic lymphoma (LPL, n  = 2). Patients received four 21-day cycles of rituximab 375 mg/m 2 (day 1), cladribine 0.10 mg/kg (days 1–3), mitoxantrone 8 mg/m 2 (day 1), and dexamethasone 8 mg/body (days 1–3), with four additional rituximab doses at 4-week intervals. Of the 33 patients, 26 achieved complete response/unconfirmed complete response, and six achieved a partial response (4 with FL, 1 with NMZB, 1 with WM). One had progressive disease (FL), and four relapsed after remission (1 with FL, 2 with MCL, 1 with LPL). R-CMD therapy was relatively convenient and effective in indolent B cell lymphoma and MCL. Nonetheless, to suppress the number and function of both B cells and T cells, comprehensive infection prevention and follow-up are necessary in the future.
ISSN:1357-0560
1559-131X
DOI:10.1007/s12032-015-0677-9